LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

LLY

723.52

-0.17%↓

JNJ

180.91

+0.71%↑

ABBV

220.83

+0.05%↑

UNH

343.05

-0.32%↓

NVO

55.34

-0.47%↓

Search

Biogen Inc

Atvērts

SektorsVeselības aprūpe

137.84 0.31

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

135.28

Max

137.65

Galvenie mērījumi

By Trading Economics

Ienākumi

394M

635M

Pārdošana

215M

2.6B

P/E

Sektora vidējais

13.46

35.69

EPS

3.02

Peļņas marža

23.995

Darbinieki

7,605

EBITDA

457M

1B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+21.72% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 29. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.9B

21B

Iepriekšējā atvēršanas cena

137.53

Iepriekšējā slēgšanas cena

137.84

Ziņu noskaņojums

By Acuity

50%

50%

131 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Biogen Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 26. sept. 18:25 UTC

Galvenie tirgus virzītāji

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

2025. g. 28. sept. 23:48 UTC

Tirgus saruna

Nikkei May Rise After Friday's Stock Gains on Wall Street -- Market Talk

2025. g. 28. sept. 23:48 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 28. sept. 23:45 UTC

Tirgus saruna

Gold Rises Amid Fed Rate-Cut Hopes -- Market Talk

2025. g. 28. sept. 23:34 UTC

Tirgus saruna

Oil Falls on Likely Technical Correction -- Market Talk

2025. g. 27. sept. 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 26. sept. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

2025. g. 26. sept. 20:54 UTC

Peļņas

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

2025. g. 26. sept. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 26. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 26. sept. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

2025. g. 26. sept. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 26. sept. 19:54 UTC

Tirgus saruna

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

2025. g. 26. sept. 19:53 UTC

Iegādes, apvienošanās, pārņemšana

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

2025. g. 26. sept. 19:40 UTC

Peļņas

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

2025. g. 26. sept. 19:24 UTC

Tirgus saruna

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

2025. g. 26. sept. 19:17 UTC

Tirgus saruna

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

2025. g. 26. sept. 19:15 UTC

Tirgus saruna

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

2025. g. 26. sept. 19:03 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 26. sept. 19:03 UTC

Tirgus saruna

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

2025. g. 26. sept. 18:50 UTC

Tirgus saruna
Peļņas

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

2025. g. 26. sept. 18:36 UTC

Tirgus saruna

Silver Closes Out Week With Strong Surge -- Market Talk

2025. g. 26. sept. 18:02 UTC

Iegādes, apvienošanās, pārņemšana

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

2025. g. 26. sept. 18:02 UTC

Iegādes, apvienošanās, pārņemšana

ING: Global Development Hasn't Received All Necessary Approvals >ING

2025. g. 26. sept. 18:02 UTC

Iegādes, apvienošanās, pārņemšana

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

2025. g. 26. sept. 17:54 UTC

Tirgus saruna

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

2025. g. 26. sept. 16:56 UTC

Tirgus saruna
Peļņas

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

2025. g. 26. sept. 16:41 UTC

Tirgus saruna
Peļņas

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

2025. g. 26. sept. 16:26 UTC

Peļņas

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

2025. g. 26. sept. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Biogen Inc Prognoze

Cenas mērķis

By TipRanks

21.72% augšup

Prognoze 12 mēnešiem

Vidējais 167.2 USD  21.72%

Augstākais 224 USD

Zemākais 118 USD

Pamatojoties uz 26 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Biogen Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

26 ratings

12

Pirkt

14

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

118.15 / 121.17Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

131 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat